|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromogranin A is an important general tumor marker for all types of carcinoid tumors.
|
11790979 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Positive chromogranin A staining of the tumor cells confirmed a diagnosis of pheochromocytoma.
|
30078826 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that circulating full-length CgA is an important inhibitor of angiogenesis and tumor growth, and that cleavage of its C-terminal region markedly reduces its activity.
|
27683038 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that abnormal secretion of CgA by neuroendocrine neoplastic cells could affect neoplastic growth and morphogenesis.
|
11830555 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor marker response (5-hydroxyindoleacetic acid [n = 7] and chromogranin A [n = 13]) at 3 months after treatment were as follows: none (n = 0, 4), partial (n = 6, 7), and complete (n = 1, 2).
|
28132407 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromogranin A fragments regulated metastatic small intestinal NEN proliferation via the AKT pathway indicating that CgA plays a far more complex role in the biology of these tumors than previously considered.
|
24260544 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This tumour entity is currently assessed by immunohistochemistry (IHC) detecting "general" NE markers such as chromogranin A (CHGA) and synaptophysin (SYP), but other markers have been considered as well.
|
24277232 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of chromogranin A, that is co-stored and co-secreted with catecholamines, may indicate tumour mass and malignancy and can be used to monitor response and relapse.
|
20675056 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In patients with NENs of the pancreas, CgA concentration was correlated with tumour grade and Ki67.
|
29724794 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results may help in selecting new antibodies with improved affinity and immunogenicity for in vivo targeting of chromogranin-A-producing tumors.
|
8631342 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers.
|
31207989 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival.
|
30366884 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In PCCs, all 28 tumors were immunoreactive for poly Sia and SYN; CrgA was detectable in 26 of 28 (93%), CT was detectable in 6 of 28 (21%), and SOM was detectable in 2 of 28 (7%) tumors.
|
7723281 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we have applied RNA in situ hybridization and immunohistochemistry assays to measure the expressions of SRRM4, NEPC markers (SYP, CD56, and CHGA), and adenocarcinoma (AdPC) markers (AR, PSA) in a series of tissue microarrays constructed from castrate-resistant prostate tumors, treatment-naïve tumors collected from radical prostatectomy, and tumors treated with neoadjuvant hormonal therapy (NHT) for 0-12 months.
|
30155992 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The finding of chromogranin A expression in some colon carcinomas suggests that a previously unrecognized subgroup of these tumors has neuroendocrine features.
|
3403722 |
1988 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Older age greater than 50 years (P = .027), higher levels of Chromogranin A (CgA) (P = .034), first-line treatment with surgery (P = .005), ki67 over 10% (P = .037), and tumor stage (P = .036) but not tumor grade (P = .22), were significantly associated with survival.
|
28026127 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast to NEN of the small bowel, there is no correlation of CgA plasma levels with tumor burden or survival.
|
29232390 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
They are typically symptomatic, most often secreting ACTH (40% of tumors) but both tumor groups share secretion of common biomarkers including chromogranin A and 5-HIAA.
|
29201449 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Possibly the differences in tumour CGA expression may contribute to differences in secretory vesicle formation and secretion in the two types of tumours.
|
18046660 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs.
|
29723285 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that Ad[CgA-E1A] replicates similarly to wild-type virus in tumor cells with neuroendocrine features, including the BON carcinoid cell line and the SH-SY-5Y neuroblastoma cell lines, whereas it is attenuated in other cell types.
|
17438105 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Prox1 also showed significant difference in expression according to chromogranin A and calcitonin immunohistochemical expression, with higher Prox1 expression in tumors with stronger chromogranin A or calcitonin staining.
|
31001799 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Netazepide for 52 weeks: cleared all tumours in 5 patients; cleared all but one tumour in one patient; reduced the number of tumours and size of the largest one in the other patients; normalized CgA in all patients; and reduced mRNA abundances of CgA and histidine decarboxylase in biopsies.
|
27704617 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Serum obtained from the patient before his death contained elevated levels of both chromogranin A (2641 ng/mL; normal level, less than 20 ng/mL) and calcitonin (517 pg/mL; normal level, less than 200 pg/mL), suggesting that the patient's principal tumor was neuroendocrine in origin.
|
1575215 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In NF-pNETs, CgA correlated with the WHO tumor grade (WHO G1 vs G2, <i>P</i> < 0.05); the linear regression relationships were found between the tumor burdens (both in pancreas and liver) and CgA concentration (<i>P</i> < 0.001); changes in CgA and NSE concentrations also reflect treatment response (<i>P</i> < 0.001).
|
29191920 |
2018 |